Date:11/24/2009

1,785,504 6,172,890 Subordinated notes payable 525,000 - Notes payable, banks 5,000,000 - Obligation under capital lease 9,362 14,725 ------------------------------------------------------------------------- Total liabilities 7,319,866 6,187,615 Commitments and contingencies Series C-2 redeemable convertible preferred stock, $.01 par value: 5,809 shares authorized, issued and outstanding at (liquidation value of $3,712,708) 2,087,584 1,990,078 Stockholders' deficit: Preferred stock, 33,622 shares authorized Series A convertible, $.01 par value: 6,243 shares authorized, issued and outstanding (liquidation value of $2,193,478) 1,150,039 1,150,039 Series B convertible, $.01 par value: 8,676 shares authorized, issued and outstanding (liquidation value of $7,267,278) 11,180,413 11,180,413 Series C-1 convertible, $.01 par value: 12,894 shares authorized and 11,789 shares issued and outstanding (liquidation value of $10,740,497) 5,294,768 5,294,768 Common stock, $.01 par value, voting, 166,378 shares authorized and 8,500 shares issued and outstanding 85 85 Additional paid-in capital 2,878,682 2,948,408 Accumulated deficit (27,821,367) (26,838,001) ------------------------------------------------------------------------- Total stockholders' deficit (7,317,380) (6,264,288) ------------------------------------------------------------------------- Total liabilities, rede
'/>"/>

Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
2. Vermillion Announces Appointment of John Hamilton to Board of Directors
3. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
4. PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend
5. Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director
6. Inimex Announces Appointment of New CEO
7. Spherix Announces the Closing of $6.3 Million Registered Direct Offering
8. Spherix Announces Results of Annual Shareholders Meeting
9. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
10. Netech Corporation Announces the Release of IPA 2000 -- Infusion Pump Analyzer for Fast and Accurate Testing of All Infusion Pumps
11. iSirona Announces Go-live at University Hospitals in Cleveland